Alomide is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 10, 2012. Details of Alomide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5457126 | Use of lodoxamide to treat ophthalmic allergic conditions |
Oct, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Alomide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Alomide's family patents as well as insights into ongoing legal events on those patents.
Alomide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alomide's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 10, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alomide Generics:
There are no approved generic versions for Alomide as of now.
About Alomide
Alomide is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating ocular allergic responses in human eyes. Alomide uses Lodoxamide Tromethamine as an active ingredient. Alomide was launched by Novartis in 1993.
Approval Date:
Alomide was approved by FDA for market use on 23 September, 1993.
Active Ingredient:
Alomide uses Lodoxamide Tromethamine as the active ingredient. Check out other Drugs and Companies using Lodoxamide Tromethamine ingredient
Treatment:
Alomide is used for treating ocular allergic responses in human eyes.
Dosage:
Alomide is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.1% BASE | SOLUTION/DROPS | Prescription | OPHTHALMIC |